PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025

Core Points - PolyPid Ltd. is a late-stage biopharma company focused on improving surgical outcomes and will report its Q3 2025 financial results on November 12, 2025 [1] - The company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and business operations [1][2] Company Overview - PolyPid utilizes its proprietary PLEX technology for controlled, prolonged-release therapeutics, enabling precise drug delivery over several days to months [4] - The lead product candidate, D-PLEX₁₀₀, aims to prevent abdominal colorectal surgical site infections, with NDA submission expected in early 2026 following positive phase 3 results [4] - The company has a pipeline that includes innovative treatments in oncology, obesity, and diabetes [4]